ArticleFrontiers in aging neuroscience2025
Explainable machine learning for early detection of Parkinson's disease in aging populations using vocal biomarkers.
Article in Frontiers in aging neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Clinically Deployable Handwriting Biomarkers of Parkinson's Disease via Multiscale Attention and Bayesian-Genetic Optimization.Brain and behavior · 2026Article
- A multimodal explainable artificial intelligence framework for interpretable Parkinson's disease prediction.Scientific reports · 2026Article
- Longitudinal voice biomarker trajectory modelling for Parkinson's disease severity: domain-adaptive transfer learning on mPower real-world smartphone data.Frontiers in digital health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Parkinson's Disease (PD) is a progressive neurodegenerative disorder that significantly affects the aging population, creating a growing burden on global health systems. Early detection of PD is clinically challenging due to the gradual and ambiguous onset of symptoms. Methods: This study presents a machine-learning framework for the early identification of PD using non-invasive biomedical voice biomarkers from the UCI Parkinson's dataset. The dataset consists of 195 sustained phonation recordings from 31 participants (23 PD and 8 healthy controls, ages 46-85). The methodology includes subject-level stratified splitting and normalization, along with BorderlineSMOTE to address class imbalance. Initially, an XGBoost model is applied to select the top 10 acoustic features, followed by a Bayesian-optimized XGBoost classifier, with the decision threshold tuned via F1-maximization on validation data. Results: On the held-out test set, the model achieves 98.0% accuracy, 0.97 macro-F1, and 0.991 ROC-AUC. This performance exceeds that of a deep neural network baseline by 4.0 percentage points in accuracy (94.0% to 98.0%), 4.3 percentage points in macro-F1 (92.7% to 97.0%), and 0.050 in AUC (0.941 to 0.991). Compared to a classical SVM, it outperforms by 7.0 percentage points in accuracy (91.0% to 98.0%), 6.5 percentage points in macro-F1 (90.5% to 97.0%), and 0.089 in AUC (0.902 to 0.991). Discussion: Model decisions are elucidated using SHAP, offering global and patient-specific insights into the influential voice features. These findings indicate the feasibility of a non-invasive, scalable, and explainable voice-based tool for early PD screening, highlighting its potential integration into mobile or telehealth diagnostic platforms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.